Akebia Therapeutics, Inc. (AKBA)
Pre-market:
| Previous close | 1.3200 |
| Open | 1.3100 |
| Bid | 1.2200 x 500 |
| Ask | 1.2600 x 100 |
| Day's range | 1.2300 - 1.3150 |
| 52-week range | 0.7800 - 2.4800 |
| Volume | |
| Avg. volume | 4,929,150 |
| Market cap | 264.09M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2800 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
Simply Wall St.When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
BenzingaFDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e
